BioCentury
ARTICLE | Politics & Policy

Industry 2, states 0 on transparency efforts

April 30, 2015 1:52 AM UTC

The author of California Assembly bill AB-463, the Pharmaceutical Cost Transparency Act of 2015, pulled the legislation from consideration by the Assembly's Committee on Health just before a hearing was to be held on Tuesday to discuss it.

The bill would have required drug companies to disclose R&D costs, SG&A costs and profits for any drug whose annual wholesale price exceeds $10,000 (see BioCentury Extra, Feb. 24). ...